Co-occurrence of two or more high-risk cytogenetic abnormalities (HRCAs) significantly worsens progression-free and overall survival in multiple myeloma (MM).
This adverse prognostic impact is consistent across newly diagnosed (NDMM) and relapsed/refractory (RRMM) settings as well as a variety of treatment modalities.
A federated meta-analysis of 24 randomized controlled trials with 13,926 MM patients confirms these findings using a standardized cytogenetic algorithm.
Recognition of ‘‘double-hit’’ cytogenetic profiles enables more precise risk stratification and informs the development of novel therapeutic approaches.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.